The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TKPHF | +25.17% | +10.52% | +2.02% | -10% |
| S&P | +14.29% | +86.82% | +13.3% | +612% |
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Its coronavirus vaccine could make it an even bigger winner.
Takeda Pharmaceutical has licensed ImmunoGen's antibody-drug conjugate technology.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $7.73B | 3.0% |
| Gross Profit | $4.21B | 8.3% |
| Gross Margin | 54.43% | 2.7% |
| Market Cap | $48.70B | 14.9% |
| Market Cap / Employee | $1.03M | 0.0% |
| Employees | 47.5K | -3.7% |
| Net Income | $673.28M | 330.4% |
| EBITDA | $2.47B | 11.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.18B | 32.9% |
| Accounts Receivable | $4.70B | 3.8% |
| Inventory | 9K | 13.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $27.24B | -9.0% |
| Short Term Debt | $3.72B | 331.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.80% | -0.6% |
| Return On Invested Capital | 2.26% | 0.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.86B | -5.9% |
| Operating Free Cash Flow | $2.10B | -6.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 65.72 | 50.34 | 173.71 | 62.24 | 102.35% |
| Price to Book | 1.05 | 0.96 | 0.96 | 1.01 | 15.10% |
| Price to Sales | 1.55 | 1.62 | 1.56 | 1.66 | 15.29% |
| Price to Tangible Book Value | -3.80 | -3.30 | -3.57 | -4.49 | 48.95% |
| Price to Free Cash Flow TTM | 15.46 | 14.66 | 11.54 | 12.69 | 5.68% |
| Enterprise Value to EBITDA | 54.00 | 30.07 | 33.87 | 30.80 | -3.72% |
| Free Cash Flow Yield | 6.5% | 6.8% | 8.7% | 7.9% | -5.37% |
| Return on Equity | 1.5% | 2.0% | 0.5% | 1.6% | -43.73% |
| Total Debt | $34.03B | $31.19B | $31.45B | $30.96B | 0.54% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
